Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00661531 · ClinicalTrials.gov registry record · Phase 2
Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy
A Phase 2 study, sponsored by Georgetown University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT00661531 is a Phase 2 study that was terminated before completion, run by Georgetown University. The registered enrollment target is 11 participants.
The verdict
NCT00661531, a Phase 2 study, was terminated before completion, sponsored by Georgetown University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
This trial seeks to confirm the response rate for estrace treatment in a patients with hormone receptor positive metastatic breast cancer heavily pre-treated with modern endocrine therapies.
Interventions
- DRUG Anastrozole
- DRUG Estrace
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2008-04 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00661531
The ClinicalTrials.gov registry entry for NCT00661531 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Anastrozole is the first listed.
NCT00661531 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00661531 about?
NCT00661531 is a clinical study titled "Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy". This trial seeks to confirm the response rate for estrace treatment in a patients with hormone receptor positive metastatic breast cancer heavily pre-treated with modern endocrine therapies.
What is the current status of trial NCT00661531?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2008-04. Estimated completion is 2015-06.
What interventions are being tested in trial NCT00661531?
The interventions under investigation include: Anastrozole (DRUG), Estrace (DRUG).
Who is sponsoring clinical trial NCT00661531?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.